Hutchison China MediTech Debt / Equity
Cos'è Debt / Equity di Hutchison China MediTech?
Debt / Equity di Hutchison China MediTech Ltd. è 0.72
Qual è la definizione di Debt / Equity?
Il rapporto debito è un rapporto finanziario che indica la proporzione relativa del patrimonio netto e del debito utilizzato per finanziare le attività di una società.
The debt to equity ratio is generally calculated by dividing debt by equity. The D/E ratio is also known as risk, gearing or leverage. The two components are often taken from the firm's balance sheet or statement of financial position (so-called book value), but the ratio may also be calculated using market values for both, if the company's debt and equity are publicly traded, or using a combination of book value for debt and market value for equity financially. Preferred stock can be considered part of debt or equity. Attributing preferred shares to one or the other is partially a subjective decision but will also take into account the specific features of the preferred shares. When used to calculate a company's financial leverage, the debt usually includes only the long-term debt.
Debt / Equity di aziende nel Health Care settore su LSE rispetto a Hutchison China MediTech
Cosa fa Hutchison China MediTech?
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases worldwide. It operates in two segments, Oncology/Immunology and Other Ventures. It manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical, and consumer health products. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and clear cell renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, an inhibitor for indolent non-Hodgkin's lymphoma (NHL), B-cell malignancies, and immune thrombocytopenic purpura; and HMPL-689 for indolent non-Hodgkin's, follicular, marginal zone, mantle cell, diffuse large B cell, chronic lymphocytic leukemia/small lymphocytic, and Hodgkin's lymphoma. The company develops HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-295 for solid tumors; and HMPL-813 and HMPL-309 EGFR inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics (Suzhou) Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Central, Hong Kong.
Aziende con debt / equity simili a Hutchison China MediTech
- Informa Plc ha Debt / Equity di 0.72
- Ashok Alco-Chem ha Debt / Equity di 0.72
- YASKAWA Electric ha Debt / Equity di 0.72
- Warehouses De Pauw SCA ha Debt / Equity di 0.72
- Warehouses De Pauw NV ha Debt / Equity di 0.72
- CyanConnode plc ha Debt / Equity di 0.72
- Hutchison China MediTech ha Debt / Equity di 0.72
- Universal Security Instruments ha Debt / Equity di 0.72
- Zimmer Biomet Inc ha Debt / Equity di 0.72
- Oriental Trimex ha Debt / Equity di 0.72
- Buru ha Debt / Equity di 0.72
- American Homes 4 Rent ha Debt / Equity di 0.72
- Langham Hospitality Investments ha Debt / Equity di 0.72